Literature DB >> 3924585

Utility of free level monitoring of antiepileptic drugs.

R H Levy, D Schmidt.   

Abstract

Criteria that were developed for monitoring free (unbound) rather than total (free plus bound) concentrations of antiepileptic drugs include extensive and variable binding to plasma proteins. Phenytoin and valproic acid belong to this category. It is shown that free drug concentration is independent of total drug concentration, whereas total drug concentration depends on free concentration and free fraction. Because antiepileptic drugs are predominantly bound to albumin, free fraction will increase in the presence of hypoalbuminemia (hepatic and renal disease, burns, and pregnancy). Free fraction also increases because of saturable binding (valproic acid) and competitive binding (valproic acid displacing phenytoin). There is suggestive evidence that side effects may be more closely related to the free, rather than to the total, plasma concentration of phenytoin. The clinical evidence that side effects or therapeutic effects are better correlated to the free, rather than the total, concentration of valproic acid or carbamazepine is not yet convincing. Knowledge of the free concentration improves our understanding of therapeutic and toxic effects of low total plasma concentrations. Further clinical trials are necessary for definitive assessment of the clinical relevance for free drug monitoring of valproic acid, carbamazepine, and phenytoin in the management of epileptic patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924585     DOI: 10.1111/j.1528-1157.1985.tb05406.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

Review 1.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 2.  Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 3.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

4.  Accuracy of Valproic Acid Concentration Correction Based on Serum Albumin.

Authors:  Aulbrey Drisaldi; Erin Weeda; Ron Neyens; Nicholas Orvin; Leonardo Bonilha; Zeke Campbell; Nicole Bohm
Journal:  Neurocrit Care       Date:  2019-04       Impact factor: 3.210

Review 5.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

6.  Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.

Authors:  M E Veronese; S McLean; R Hendriks
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

7.  Epileptic patients refractory to drug therapy.

Authors:  L Paris; M Giardina; R Pacifici; S Pichini; P Zuccaro; G Sideri
Journal:  Ital J Neurol Sci       Date:  1991-10

Review 8.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 9.  Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

10.  Factors affecting the free plasma fraction of phenytoin in patients with epilepsy.

Authors:  M C Jiménez; J A Durán; J A Abad In
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.